Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AbbVie’s Skyrizi becomes first drug to win FDA nod for Crohn’s disease

By Brian Buntz | June 17, 2022

AbbVieAbbVie (NYSE:ABBV) has announced that FDA has approved Skyrizi (risankizumab-rzaa) as the first interleukin-23 (IL-23) inhibitor to treat adults with moderately to severely active Crohn’s disease (CD).

Skyrizi is also FDA-approved as a treatment for moderate to severe plaque psoriasis and active psoriatic arthritis.

IL-23 inhibitors have surged in popularity recently, given their ability to treat diseases such as plaque psoriasis.

Janssen’s Stelara (ustekinumab), which inhibits both IL-12 and IL-23, has racked up the most indications. It is now FDA-approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Stelara was first FDA-approved in 2009.

Skyrizi is a newer drug, winning FDA approval for plaque psoriasis in 2019.

A 2019 analysis found that Skyrizi had higher efficacy than placebo and Stelara in treating moderate-to-severe chronic plaque psoriasis.

Skyrizi

[Image courtesy of AbbVie]

AbbVie won the most recent indication for the drug by providing data from three clinical trials focused on moderately to severely active Crohn’s disease known as ADVANCE, MOTIVATE and FORTIFY1-4.

In the studies, Skyrizi showed significant improvements in endoscopic response compared to placebo as both an induction and maintenance therapy.

“We are proud to offer the first new treatment option in six years for moderately to severely active CD, which may provide patients with a meaningful level of endoscopic improvement,” said Dr. Thomas Hudson, senior vice president, research and development, chief scientific officer, AbbVie, in a press release. “With more than 30 ongoing or planned trials in inflammatory bowel disease, AbbVie is committed to advancing the standards of care for patients by exploring and investing in research for those living with immune-mediated, gastroenterological conditions.”

AbbVie partnered with Boehringer Ingelheim in developing Skyrizi, which was initially known as BI 655066. In 2016, the companies announced they were developing the drug for psoriasis while testing its potential in Crohn’s disease, psoriatic arthritis and asthma.

AbbVie paid an upfront payment of $595 million for the drug plus additional milestone payments and sales royalties.


Filed Under: Dermatology, Gastroenterology
Tagged With: AbbVie, Crohn's disease
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bristol Myers Squibb
FDA approves new Opdivo indications for upper gastroesophageal cancers
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen touts positive Tremfya and Stelara data for IBD at Digestive Disease Week
AbbVie
AbbVie’s Rinvoq supports clinical remission in Phase 3 Crohn’s disease study
First Wave BioPharma
First Wave BioPharma stock tanks after announcing COVID-19 therapy trial data

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50